Browsing Tag
liver disease therapeutics
1 post
Madrigal Pharmaceuticals adds Phase 2 DGAT-2 inhibitor ervogastat to MASH pipeline under global licensing agreement
Find out how Madrigal Pharmaceuticals is expanding its MASH strategy with a global license for ervogastat, a Phase 2 DGAT-2 inhibitor.